



Top Denied Drugs (NE States—2014 YTD)

	Allowed Amount	Insurance Amount	Non-Reimbursed Amount	DTF	DTP	Payer Responses	True Denials	True Denials %	Distinct Patients	Distinct Claims
	\$222,662,949.40	\$181,340,428.60	\$41,322,520.80	9.0	34.4	390172	21483	6%	19236	128931
Cyramza	\$18,647.60	\$31,185.65	\$(12,538.05)	4.5	22.63	13	4	31%	8	12
Adcetris	\$59,386.60	\$91,390.60	\$(32,004.00)	7.0	43.3	8	2	25%	2	6
Kadcyla	\$3,839,121.44	\$3,003,208.43	\$835,913.01	16.9	50.0	720	168	23%	73	408
Provenge	\$4,318,992.38	\$2,860,141.54	\$1,457,850.54	14.4	33.5	157	31	20%	39	99
Doxil	\$734,822.76	\$726,213.60	\$8,609.15	13.5	37.2	538	84	16%	116	393
Perjeta	\$2,330,867.52	\$2,040,727.25	\$290,140.27	11.7	46.1	659	102	15%	105	446
Arzerra	\$230,964.91	\$166,194.33	\$64,770.58	34.9	24.5	26	4	15%	10	25
Yervoy	\$3,220,455.49	\$2,120,450.49	\$1,100,005.00	4.4	40.5	90	13	14%	27	61
Gazyva	\$36,858.46	\$95,930.48	\$(59,072.02)	4.5	22.7	44	5	11%	7	35
Aranesp	\$4,746,881.72	\$3,771,481.85	\$975,399.87	12.0	33.8	6257	552	11%	1047	4281